carecentrix

Provider Newsflash
March 2022

Company Announcement/Recall – Adamis Pharmaceuticals Corp

Purpose of this communication:

We are writing to inform you that the FDA has published notice of a voluntary recall issued by Adamis Pharmaceuticals, Corp. of certain lots of SYMJEPI (EPINEPHRINE) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) Pre-filled Single-dose Syringes due to the potential clogging of the needle preventing the dispensing of epinephrine. US WorldMeds (USWM) exclusively markets and distributes SYMJEPI in the United States and will handle the entire recall process for Adamis.

Product	Strength	NDC	Lot	Expiration
SYMJEPI (epinephrine) Injection	0.15 mg/0.3 mL	78670-131-02	21101Y	11/30/2022
	0.3 mg/0.3 mL	78670-130-02	21041W	8/31/2022
			21081W	11/30/2022
			21102W	2/28/2023

What do I need to do?

- Please review the following recall notice: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/adamis-pharmaceuticals-corporation-issues-nationwide-voluntary-recall-symjepir-epinephrine-injection?utm_medium=email&utm_source=govdelivery
- Notify impacted patients and facilitate the repair, replacement and/or resolution of the recall, according to the guidelines issued by the manufacturer in the notification.
- Confirm if you have any CareCentrix patients affected by this recall and notify the CareCentrix Quality Department by faxing information to: 919-792-6718 Attn: Quality Department.

Thank you in advance for your cooperation and continued partnership.